Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Adhesion and Integrins
share announcement

Adhesion and Integrins

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 October 2012) | Viewed by 21989

Special Issue Editor

Prof. Kairbaan Hodivala-Dilke

E-Mail Website
Guest Editor
Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London ECIM 6BQ, UK
Interests: tumor angiogenesis; blood vessels; chemoresistance; cancer-associated fibroblasts; pericytes; focal adhesion kinase; integrins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer initiation, growth, progression and metastasis are all stages of the disease that involve changes in both cell-cell and cell-matrix adhesion.  Such changes occur not only the tumour cell compartment but also in the stromal compartment, with changes in the adhesive capacity of immune cells, tumour associated fibroblasts, endothelial cells and so on. It is increasing evident that blockade of such adhesion molecules may have therapeutic value. The special issue of Cancers on ‘Adhesion and Integrins’ will include original research articles and review articles on the influence of adhesion molecules in cancer development and how we can exploit such changes for therapeutic advance.

Prof. Kairbaan Hodivala-Dilke
Guest Editor

Keywords

  • Integrins
  • Cadherins
  • Metastasis
  • Invasion
  • Angiogenesis
  • Stroma
  • Cancer
  • Immune infiltration

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

234 KiB  
Review
Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
by Florence Schaffner, Anne Marie Ray and Monique Dontenwill
Cancers 2013, 5(1), 27-47; https://doi.org/10.3390/cancers5010027 - 15 Jan 2013
Cited by 152 | Viewed by 11744
Abstract
Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also [...] Read more.
Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors. Full article
(This article belongs to the Special Issue Adhesion and Integrins)
714 KiB  
Review
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis
by Mark Sutherland, Andrew Gordon, Steven D. Shnyder, Laurence H. Patterson and Helen M. Sheldrake
Cancers 2012, 4(4), 1106-1145; https://doi.org/10.3390/cancers4041106 - 26 Oct 2012
Cited by 56 | Viewed by 9887
Abstract
Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital [...] Read more.
Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital role in the cross-talk between the cell and extracellular matrix, enhancing the growth, migration, invasion and metastasis of cancer cells. Progression and metastasis of prostate adenocarcinoma is strongly associated with changes in integrin expression, notably abnormal expression and activation of the β3 integrins in tumour cells, which promotes haematogenous spread and tumour growth in bone. As such, influencing integrin cell expression and function using targeted therapeutics represents a potential treatment for bone metastasis, the most common and debilitating complication of advanced prostate cancer. In this review, we highlight the multiple ways in which RGD-binding integrins contribute to prostate cancer progression and metastasis, and identify the rationale for development of multi-integrin antagonists targeting the RGD-binding subfamily as molecularly targeted agents for its treatment. Full article
(This article belongs to the Special Issue Adhesion and Integrins)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop